

26<sup>th</sup> September, 2019

### BSE Limited

Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai – 400001. Scrip Code: 524404 National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051. Symbol: MARKSANS

Dear Sirs,

Sub: Proceedings of the 27<sup>th</sup> Annual General Meeting of Marksans Pharma Limited held on Thursday, September 26, 2019.

This is to inform you that the 27<sup>th</sup> Annual General Meeting ("AGM") of Marksans Pharma Limited ("the Company") was held on Thursday, September 26, 2019 and the business mentioned in the Notice dated August 9, 2019 was transacted.

Summary of proceedings under Regulation 30, Part-A of Schedule-III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is given below:

### 1. Date, Time and Venue of the Meeting:

The AGM of the Members of the Company was held on Thursday, September 26, 2019 at 10:30 a.m. at GMS Banquet, Next to D. N Nagar Metro Station, Opp. Indian Oil Nagar, New Link Road, Andheri (West), Mumbai – 400 053. The meeting concluded at 11:25 a.m. on the same day.

### 2. Brief details of the items deliberated at the meeting and the results thereof:

- a. Mr. Mark Saldanha, Chairman chaired the proceedings of the meeting.
- b. The requisite quorum being present, the Chairman called the meeting to order.
- c. The Chairman then delivered his speech.
- d. The following items of Ordinary and Special business as per the Notice of AGM dated August 9, 2019, were transacted at the meeting:

### **Ordinary Business**

 Consideration and adoption of the Standalone and Consolidated Audited Financial Statements of the Company for the financial year ended 31<sup>st</sup> March, 2019 together with the reports of the Board of Directors' and the Auditors' thereon.

# Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com www.marksanspharma.com



# Marksans Pharma Ltd.

- Declaration of dividend of Rs. 0.05 (i.e. 5%) on Equity Shares of Re. 1/- each face value and dividend of Rs. 7.00 (i.e. 7%) on Redeemable Cumulative Preference Shares of Rs. 100/- each face value for the financial year ended March 31, 2019.
- Re-appointment of Mrs. Sandra Saldanha (DIN: 00021023), who retired by rotation and being eligible, offered herself for re-appointment.

#### **Special Business**

- Appointment of Mr. Abhinna Sundar Mohanty (DIN: 00007995) as an Independent Director of the Company.
- Approval of Marksans Employees Stock Option Scheme 2019.
- e. Clarifications were provided to the queries raised by the members at the meeting.
- f. The Chairman informed the members that Jinesh Dedhia & Associates, Practicing Company Secretaries were appointed as Scrutinizer for the purpose of scrutinizing the remote evoting process and voting through ballot paper at the venue of the AGM in a fair and transparent manner.
- g. The Chairman further informed that results of voting would be announced by Saturday, 28<sup>th</sup> September, 2019 by intimation to the Stock Exchanges and would also be placed on the website of the Company www.marksanspharma.com.

### 3. Manner of approval:

- Pursuant to the provisions of the Companies Act, 2013 and Regulation 44 of the Listing Regulations, the Company had provided remote e-voting facility to its members to cast votes electronically, on all the resolutions set out in the notice.
- Further, the facility for voting through ballot was also made available to the members who were present at the AGM and had not cast their votes by remote e-voting.

You are requested to take note of the same.

Thanking You.

Yours faithfully, For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

## Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: info@marksanspharma.com www.marksanspharma.com